Taiwan:6576.TWO

Foresee Pharmaceuticals Enters Exclusive License Agreement with Accord Healthcare

TAIPEI, , Feb. 11, 2019 /PRNewswire/ -- An exclusive license agreement for the commercialisation of Foresee Pharmaceutical's (6576.TWO) novel FP-001 program (leuprorelin depot), Leuprolide Mesylate Injectable Suspension (LMIS) ready-to-use subcutaneous depot formulations has been granted to Accor...

2019-02-11 18:30 1353

Foresee Pharmaceuticals Announces Completion of Last Patient Visit in Registration Phase 3 Study of LMIS 25 mg (fp-001) for the Treatment of Advanced Prostate Cancer

TAIPEI, , Nov. 26, 2018 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) today announced that all patients had completed participation in its Phase 3, multinational, multicenter trial of FP-001/LMIS (Leuprolide Mesylate Injectable Suspension) 25 mg, a three-month, ready-to-use subcuta...

2018-11-26 21:30 1127

Foresee Pharmaceuticals Announces Results from Phase 1 Clinical Studies

TAIPEI, , Dec. 4, 2017 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), announced today that it has successfully completed Phase 1 single and multiple ascending dose (SAD/MAD) clinical studies with FP-025, its novel, highly selective, oral small-molecule matrix metallopr...

2017-12-04 23:06 1203

Foresee Pharmaceuticals Announces CEO Appointment

TAIPEI, , July 31, 2017 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), announced today the appointment of Dr.Lawrence Gan to the position of Chief Executive Officer (CEO), effective onAug. 1st, 2017. Dr. Lawrence Gan will lead Foresee's global strategy including po...

2017-07-31 18:53 2736

Week's Top Stories